The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
Ramon Salazar
No relevant relationships to disclose
Jan Willem de Waard
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
John Marshall
No relevant relationships to disclose
Joost Klaase
No relevant relationships to disclose
Jacobus Van Der Hoeven
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose
Frédéric Bibeau
No relevant relationships to disclose
Lisette Stork-Sloots
Employment or Leadership Position - Agendia
Robert Rosenberg
Research Funding - Agendia